MedWorm: Gene TherapyMedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest headlines from journals and sites in the Gene Therapy category.A comparative analysis of constitutive and cell-specific promoters in the adult mouse hippocampus using lentivirus vector-mediated gene transfer- September 5, 2008 Viral vectors provide powerful tools for transgene delivery to the mammalian brain to assess the effects of therapeutic proteins, antisense RNAs or small interfering RNAs. A key advantage of such approaches is that specific brain regions implicated in a particular disease can be independently targeted.To optimize transgene expression in sub-regions of the mouse hippocampus and with a view towards devising gene therapy strategies for Alzheimer's disease, we designed lentivirus-based reporter...http://dx.doi.org/10.1002%2Fjgm.1249 Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using m6 promoter- September 5, 2008 Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter Cancer Gene Therapy advance online publication, September 5, 2008. doi:10.1038cgt.2008.59 Authors: M Ahn, S-J Lee, X Li, J A Jim&233;nez, Y-P Zhang, K-H Bae, Y Mohammadi, C Kao & T A Gardner (Source: Cancer Gene Therapy) MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.http://dx.doi.org/10.1038/cgt.2008.59 Gene therapy prevents blindness in mitochondrial dysfunction- September 4, 2008 Scientists have created an animal model suitable for testing and validating gene therapies for treatment of a common mitochondrial dysfunction that causes loss of vision. (Source: Huliq Health News)http://www.huliq.com/11/67696/gene-therapy-prevents-blindness-mitochondrial-dysfunction Inhibition of pancreatic carcinoma growth by adenovirus-mediated human interleukin-24 expression in animal model- September 4, 2008 Cancer Biotherapy & Radiopharmaceuticals Aug 2008, Vol. 23, No. 4: 425-434. Interleukin-24 (IL-24) has been shown to be a tumor-suppressor gene and the protein product found to be constitutively expressed by melanocytes, nerve cells, and some primary melanomas. The potential effect of adenovirus (AdV)-mediated IL-24 gene therapy ... (Source: Cancer Biotherapy and Radiopharmaceuticals)http://www.liebertonline.com/doi/abs/10.1089/cbr.2008.0461?ai=sx&mi=o0fy&af=R Animal study clears way for gene therapy trial in limb girdle muscular dystrophy.- September 4, 2008 Page: 1,8DOI: 10.109701.NT.0000335574.79492.d0Authors: SAMSON, KURT (Source: Neurology Today)http://www.neurotodayonline.com/pt/re/neurotoday/abstract.00132985-200808070-00002.htm Previous claims of sirna therapeutic effects called into question by report in human gene therapy- September 4, 2008 The many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA to activate an immune response, according to a paper in the September 2008 issue (Volume 19, Number 9) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (Source: Genetics News From Medical News Today) MedWorm Sponsored Message: Find out...http://www.medicalnewstoday.com/articles/120166.php Sola dosis facit venenum. leukemia in gene therapy trials: a question of vectors, inserts and dosage- September 4, 2008 Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage&63; Leukemia advance online publication, September 4, 2008. doi:10.1038leu.2008.219 Authors: F J T Staal, K Pike-Overzet, Y Y Ng & J J M van Dongen (Source: Leukemia)http://dx.doi.org/10.1038/leu.2008.219 Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of scid-x1- September 3, 2008 Previously, several individuals with X-linked SCID (SCID-X1) were treated by gene therapy to restore the missing IL-2 receptor &x003b3; (IL2RG) gene to CD34+ BM precursor cells using gammaretroviral vectors. While 9 of 10 patients were successfully treated, 4 of the 9 developed T cell leukemia 31&x02013;68 months after gene therapy. In 2 of these cases, blast cells contained activating vector insertions near the LIM domain&x02013;only 2 (LMO2) proto-oncogene. Here, we report data on the 2 most..http://www.jci.org/articles/view/35700 Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of scid-x1 patients- September 3, 2008 X-linked SCID (SCID-X1) is amenable to correction by gene therapy using conventional gammaretroviral vectors. Here, we describe the occurrence of clonal T cell acute lymphoblastic leukemia (T-ALL) promoted by insertional mutagenesis in a completed gene therapy trial of 10 SCID-X1 patients. Integration of the vector in an antisense orientation 35 kb upstream of the protooncogene LIM domain only 2 (LMO2) caused overexpression of LMO2 in the leukemic clone. However, leukemogenesis was likely...http://www.jci.org/articles/view/35798 Insulin-like growth factor-1 gene therapy and cell transplantation in diabetic wounds- September 3, 2008 Impaired wound healing is a frequent phenomenon in diabetes mellitus. However, little is known of the fundamental cause of this pathology. The present study examined the effect of human insulin-like growth factor (hIGF)-1 overexpression in combination with autologous cell transplantation to diabetic wounds in a preclinical large-animal model.Diabetes was induced in Yorkshire pigs with streptozotocin. Keratinocytes were cultured and transfected with hIGF-1 or LacZ transgene. Plasmids were...http://dx.doi.org/10.1002%2Fjgm.1251 |